Zydus Lifesciences Limited
Zydus Lifesciences Limited engages in the research, development, production, marketing, distribution, and sale of pharmaceutical products in India, the United States, and internationally. It operates through two segments: Pharmaceuticals and Consumer Products. It offers active pharmaceutical ingredients, finished dosage formulations, generics, specialty, biosimilars, vaccines, novel products, consumer wellness and animal health products under the Everyuth, Nutralite, SugarFree, Complan, Glucon-D, and Nycil brands. The company also provides a pipeline of biological products in the areas of oncology, autoimmune disease, nephrology, inflammation, rheumatology, hepatology, and infectious illnesses, as well as in the therapeutic areas of pain management, neurology, metabolic disorder, and neurology. In addition, it engages in the investment, animal health and veterinary, pharmacy retail, and manpower supply and administration activities. Further, it develops and markets products for orthopaedic surgery, including pathologies affecting the hip and knee. The company was formerly known as Cadila Healthcare Limited and changed its name to Zydus Lifesciences Limited in February 2022. Zydus Lifesciences Limited was founded in 1952 and is headquartered in Ahmedabad, India. Zydus Lifesciences Limited is a subsidiary of Zydus Family Trust.
Valuation
Profitability
Returns
Solvency
AI Summary
Indian StockStrengths1
- Strong 5-year net profit CAGR of 19.5%
Concerns1
- Negative free cash flow (βΉ5 Cr)
Rule-based from financial data. Not advice.
Monthly Returns
Year-to-Date ROI
Historical Volatility
Historical Performance
Revenue, profitability, and cash flow trends (βΉ Crores)
Revenue (10Y)
Operating Income (10Y)
Net Profit (10Y)
Operating Margin % (10Y)
Dividend Payout % (10Y)
Free Cash Flow (10Y)
Growth Summary
Latest fiscal year: Mar 2025
Historical Growth
Year-by-year revenue, profitability, and cash flow (βΉ Crores, last 10 years)
| Year | Revenue | Op. Income | Net Profit | CFO | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|---|
| Mar 2025 | βΉ15.12 K Cr | β | βΉ5.78 K Cr | β | β | 27.3% | 39.7% | 67.8% |
| Mar 2024 | βΉ10.82 K Cr | β | βΉ3.44 K Cr | β | β | 21.9% | 23.9% | 125.1% |
| Mar 2023 | βΉ8.73 K Cr | β | βΉ1.53 K Cr | β | β | 11.2% | 11.4% | 78.2% |
| Mar 2022 | βΉ7.84 K Cr | β | βΉ858.00 Cr | β | β | 6.5% | 0.7% | -41.9% |
| Mar 2021 | βΉ7.78 K Cr | β | βΉ1.48 K Cr | β | β | 11.6% | 22.6% | 4.5% |
| Mar 2020 | βΉ6.35 K Cr | β | βΉ1.41 K Cr | β | β | 12.5% | 5.1% | -4.9% |
| Mar 2019 | βΉ6.04 K Cr | β | βΉ1.49 K Cr | β | β | 17.3% | 3.9% | 36.2% |
| Mar 2018 | βΉ5.81 K Cr | β | βΉ1.09 K Cr | β | β | 14.1% | 79.8% | 64.8% |
| Mar 2017 | βΉ3.23 K Cr | β | βΉ662.00 Cr | β | β | 10.0% | -54.1% | -67.5% |
| Mar 2016 | βΉ7.03 K Cr | β | βΉ2.04 K Cr | β | β | 32.5% | 33.1% | 60.3% |
Financial Statements
Income statement, balance sheet, and cash flow (βΉ Crores, as reported)
Consolidated Figures in USD Millions.
| Unnamed: 0 | TTM |
|---|---|
| Revenue / Net Sales | 13,795 |
| Total Expenses | 7,636 |
| EBIT / Operating Profit | 6,158 |
| OPM % | 45% |
| Other Income | 962 |
| Finance Costs | 504 |
| Depreciation & Amortisation | 526 |
| Profit Before Tax | 6,090 |
| Tax % | - |
| Net Profit / PAT | 4,826 |
| EPS (βΉ) | 47.95 |
| Dividend Payout % | - |
Peer Comparison
Healthcare sector peers, ranked by market cap
| Company | Market Cap | Revenue | P/E | P/B | EV/EBITDA | Rev G 1Y |
|---|---|---|---|---|---|---|
| Zydus Lifesciences Limitedthis co. | βΉ90.64 K Cr | βΉ15.12 K Cr | 18.80 | 4.19 | 18.39 | 39.7% |
| Sun Pharmaceutical Industries Ltd. | βΉ4.15 L Cr | βΉ23.00 K Cr | 88.70 | 17.43 | 72.30 | 13.5% |
| Divi's Laboratories Ltd. | βΉ1.71 L Cr | βΉ9.20 K Cr | 67.90 | 11.13 | 67.21 | 20.0% |
| Torrent Pharmaceuticals Ltd. | βΉ1.33 L Cr | βΉ9.68 K Cr | 62.50 | 15.76 | 45.64 | 13.5% |
| Cipla Ltd. | βΉ1.17 L Cr | βΉ19.05 K Cr | 22.50 | 3.51 | 19.33 | 14.9% |
| Apollo Hospitals Enterprises Ltd. | βΉ1.05 L Cr | βΉ8.20 K Cr | 75.00 | 11.28 | 54.44 | 12.8% |
| Max Healthcare Institute Limited | βΉ1.00 L Cr | βΉ2.66 K Cr | 144.00 | 11.76 | 96.84 | 13.8% |
| Industry Average | β | βΉ3.29 K Cr | 98.63 | 8.11 | 65.50 | 20.2% |